Drug delivery systems to prevent peritoneal metastasis after surgery of digestives or ovarian carcinoma: A review

Functional biomaterials for the diagnosis and treatment of peritoneal surface malignancies

“…The materials used in the sustained release of intraperitoneal chemotherapy drugs mainly include particles (microparticles, nanoparticles, micelles, macromolecules, liposomes, etc.) and degradable hydrogel‐based sustained‐release materials 63 …”

CO2-Driven Nebulization of pH-Sensitive Supramolecular Polymers for Intraperitoneal Hydrogel Formation and the Treatment of Peritoneal Metastasis

“…1,2 Dur-ing HIPEC, chemotherapeutic agents are administered locally to target any residual microscopic disease. 6,7 This approach aims for increased intraperitoneal (IP) drug concentrations and lower systemic toxicity, since the peritoneal-plasma barrier causes the peritoneal clearance to be significantly lower compared to the plasma clearance. Unresectable PM is treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC), a locoregional drug delivery method where chemotherapeutic solutions are nebulized during laparoscopic surgery.…”

“…Beside serving as a depot for the sustained delivery of small molecules, polymer-drug conjugates or NPs, hydrogels can be applied as physical barriers to prevent peritoneal adhesions, a frequent complication of intra-abdominal surgery. 6,9,16 Combined with high pressure nebulization (ePIPAC) as an administration method, hydrogels can be seen as ideal drug delivery systems to treat PM, since a homogeneous IP distribution and prolonged drug release are thought to enhance treatment efficacy. However, previous research has shown that aerosolization of hydrogels is highly challenging due to the high viscosity of gels, which can be linked to the MW, hydrophilicity, concentration and flexibility of the poly- mers.…”

“…Because of its late diagnosis, peritoneal metastasis (PM) originating from epithelial ovarian cancer is linked to poor prognosis. Additional to intravenous platinum- and taxane-based cytostatics, selected patients are treated with cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC). , During HIPEC, chemotherapeutic agents are administered locally to target any residual microscopic disease. , This approach aims for increased intraperitoneal (IP) drug concentrations and lower systemic toxicity, since the peritoneal-plasma barrier causes the peritoneal clearance to be significantly lower compared to the plasma clearance. , …”

Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model

“…The gel-state insures in situ gelification and consequently local and prolonged action 10 . A review of the various delivery systems proposed in this pathology was recently submitted by our group 11 . Based on this survey and the clinical requirements, the composition of the thermogel was chosen with the following objectives i) able to gelify around 27-30°C providing both a transferrable manufacturing process and facilitating local injection of the solution in the peritoneal cavity which will turn to a gel at body temperature ii) viscoelastic properties tending towards ideally elastic (tan  lower than 0.1) iii) prevent tumor cell adhesion iv) able to carry and release a combination of cytotoxic agents v) involving no local or systemic toxicity for safety of use.…”